Drug Profile
PF 06753512
Alternative Names: PF-06753512; PF-6753512; PrCa VBIR; VBIR-1Latest Information Update: 24 Jul 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 04 Jun 2021 Efficacy and adverse events data from a phase I trial in Prostate cancer presented at 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
- 09 Mar 2021 Pfizer terminates a phase I trial in Prostate cancer (Second-line therapy or greater) in USA (parenteral) (NCT02616185)
- 02 Dec 2020 Discontinued - Phase-I for Prostate cancer (Second-line therapy or greater) in USA (Parenteral) (Pfizer pipeline, July 2020)